公开(公告)号：WO2012172566A2

公开(公告)日：2012-12-20

申请号：PCT/IN2012000416

申请日：2012-06-13

Applicant: PANACEA BIOTEC LTD ,  JAIN RAJESH ,  TREHAN SANJAY ,  DAS JAGATTARAN ,  NANDA GURMEET KAUR ,  THUNGATHURTHI SASTRY V R S ,  SINGH NISHAN ,  SHARMA SUDHIR KUMAR

Inventor： JAIN RAJESH ,  TREHAN SANJAY ,  DAS JAGATTARAN ,  NANDA GURMEET KAUR ,  THUNGATHURTHI SASTRY V R S ,  SINGH NISHAN ,  SHARMA SUDHIR KUMAR

IPC: C07H15/203

CPC classification number: A61K31/7048 ,  A61K31/70 ,  C07D309/10 ,  C07D401/04 ,  C07D493/08 ,  C07H7/04 ,  C07H9/04 ,  C07H13/04 ,  C07H13/12 ,  C07H15/04 ,  C07H19/01

Abstract: The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula (I), their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula (I) and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).

Abstract translation: 本发明涉及式（I）的新化合物，其药学上可接受的衍生物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂合物。 本发明还涉及合成式（I）的新化合物，其药学上可接受的衍生物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂合物的方法。 本发明还提供包含式（I）的新型化合物和治疗或预防可通过抑制葡萄糖转运蛋白-2（SGLT-2）调节或归一化的一种或多种病症或疾病的药物组合物。

公开(公告)号：WO2012057590A3

公开(公告)日：2012-07-26

申请号：PCT/KR2011008222

申请日：2011-10-31

Applicant: SAMSUNG ELECTRONICS CO LTD ,  VAN LIESHOUT GERT JAN ,  KIM SOENG-HUN ,  BAGHEL SUDHIR KUMAR ,  MANEPALLI VENKATESWARA RAO

Inventor： VAN LIESHOUT GERT JAN ,  KIM SOENG-HUN ,  BAGHEL SUDHIR KUMAR ,  MANEPALLI VENKATESWARA RAO

IPC: H04W88/06 ,  H04B15/00 ,  H04W16/14 ,  H04W74/00

CPC classification number: H04W72/082 ,  H04B1/406 ,  H04B15/00 ,  H04B2215/062 ,  H04W16/14 ,  H04W72/1215 ,  H04W76/048 ,  H04W88/02 ,  H04W88/06

Abstract: The present invention provides a method and apparatus for handling in-device co-existence interference in user equipment. In one embodiment, a long term evolution (LTE)activity scheduled to be performed during an inactive time period of a LTE module in user equipment is determined. It is determined whether the LTE module is to be allowed to perform the LTE activity during the inactive time period. If the LTE activity is to be allowed, then the LTE module is allowed to perform the LTE activity during the inactive time period. Otherwise, the LTE module is not allowed to perform the LTE activity during the inactive time period to provide interference free time for an ISM module in the user equipment. Moreover, the disallowed LTE activity is scheduled to be performed during an active time period following the inactive time period.

Abstract translation: 本发明提供了一种用于处理用户设备中的装置间共存干扰的方法和装置。 在一个实施例中，确定在用户设备中的LTE模块的非活动时段期间计划执行的长期演进（LTE）活动。 确定是否允许LTE模块在非活动时间段内执行LTE活动。 如果要允许LTE活动，则允许LTE模块在非活动时间段内执行LTE活动。 否则，不允许LTE模块在非活动时间段内执行LTE活动，为用户设备中的ISM模块提供无干扰时间。 此外，不活动的LTE活动被调度为在非活动时间段之后的活动时间段期间执行。

公开(公告)号：WO2012093901A2

公开(公告)日：2012-07-12

申请号：PCT/KR2012/000175

申请日：2012-01-06

Applicant: SAMSUNG ELECTRONICS CO., LTD. ,  BAGHEL, Sudhir Kumar ,  MANEPALLI, Venkateswara Rao

Inventor： BAGHEL, Sudhir Kumar ,  MANEPALLI, Venkateswara Rao

IPC: H04W24/10 ,  H04W36/14

CPC classification number: H04W24/02 ,  H04L5/0005 ,  H04W16/14 ,  H04W36/0094 ,  H04W72/1215

Abstract: The present invention provides a method and apparatus for handling in-device coexistence interference in user equipment. In one embodiment, a method includes receiving a list of non-serving LTE frequencies from a base station. The method includes configuring the non-serving LTE frequencies for performing measurements on the configured non-serving LTE frequencies. The method also includes detecting likelihood of in-device coexistence interference between at least one of the non-serving LTE frequencies and an ISM frequency when an ISM activity is ongoing on the ISM frequency.

Abstract translation: 本发明提供了一种用于处理用户设备中的设备内共存干扰的方法和设备。 在一个实施例中，一种方法包括从基站接收非服务LTE频率的列表。 该方法包括配置非服务LTE频率以对配置的非服务LTE频率执行测量。 该方法还包括当ISM活动在ISM频率上正在进行时，检测至少一个非服务LTE频率与ISM频率之间的设备内共存干扰的可能性。

公开(公告)号：WO2012023839A2

公开(公告)日：2012-02-23

申请号：PCT/KR2011006159

申请日：2011-08-19

Applicant: SAMSUNG ELECTRONICS CO LTD ,  BAGHEL SUDHIR KUMAR ,  MANEPALLI VENKATESWARA RAO

Inventor： BAGHEL SUDHIR KUMAR ,  MANEPALLI VENKATESWARA RAO

IPC: H04J11/00 ,  H04B7/26 ,  H04L1/18 ,  H04W24/00

CPC classification number: H04W16/00 ,  H04L1/0026 ,  H04L1/0027 ,  H04L5/001 ,  H04W24/02 ,  H04W88/08

Abstract: The present invention provides methods and apparatusfor activating and deactivating secondary cells in a carrier aggregation environment. In one embodiment, a medium access control (MAC) control element (CE) command is received from a base station for activating/deactivating a secondary cell associated with user equipment (UE). Then, the secondary cell configured for user equipment is activated/deactivated based on the MAC CE command. Further, a first uplink grant is received from the base station upon activation/deactivation of the secondary cell. Accordingly, quality information (e.g., channel quality information and sounding reference signal information) associated with the cell(s) is transmitted to the base station in the received first uplink grant over a physical uplink shared channel. Furthermore, a hybrid automatic repeat request entity associated with the secondary cell is reset.

Abstract translation: 本发明提供了用于在载波聚合环境中激活和去激活辅助小区的方法和设备。 在一个实施例中，从基站接收用于激活/去激活与用户设备（UE）相关联的辅助小区的媒体接入控制（MAC）控制元素（CE）命令。 然后，基于MAC CE命令来激活/去激活为用户设备配置的辅小区。 此外，在辅小区的激活/去激活时从基站接收第一上行链路许可。 因此，在物理上行链路共享信道上，在接收到的第一上行链路许可中将与小区相关联的质量信息（例如，信道质量信息和探测参考信号信息）发送到基站。 此外，重置与辅小区相关联的混合自动重传请求实体。

公开(公告)号：WO2011070592A2

公开(公告)日：2011-06-16

申请号：PCT/IN2010000796

申请日：2010-12-09

Applicant: PANACEA BIOTEC LTD ,  JAIN RAJESH ,  TREHAN SANJAY ,  THUNGATHURTHI SASTRY V R S ,  NANDA GURMEET KAUR ,  DAS JAGATTARAN ,  MAGADI SITARAM KUMAR ,  SHARMA SUDHIR KUMAR

Inventor： JAIN RAJESH ,  TREHAN SANJAY ,  THUNGATHURTHI SASTRY V R S ,  NANDA GURMEET KAUR ,  DAS JAGATTARAN ,  MAGADI SITARAM KUMAR ,  SHARMA SUDHIR KUMAR

CPC classification number: C07H15/04 ,  C07D309/10

Abstract: The present invention relates to novel compounds of Formula (I), their pharmaceutically acceptable derivatives, analogs, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, analogs, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2). The invention also relates to the use of compounds of Formula I, their pharmaceutically acceptable derivatives, analogs, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof, for the manufacture of a medicament for the prophylaxis, amelioration and/or treatment of conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2) and the related diseases, disorders and conditions, in a subject in need thereof.

Abstract translation: 本发明涉及式（I）的新化合物，其药学上可接受的衍生物，类似物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂合物。 本发明还涉及合成式I的新化合物，其药学上可接受的衍生物，类似物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂合物的方法。 本发明还提供包含式I的新化合物和治疗或预防一种或多种可通过抑制葡萄糖转运蛋白-2（SGLT-2）调节或归一化的病症或疾病的药物组合物。 本发明还涉及式I化合物，其药学上可接受的衍生物，类似物，互变异构体形式，异构体，多晶型物，前体药物，代谢物，盐或溶剂合物在制备用于预防和/或改善 在有需要的受试者中通过抑制葡萄糖转运蛋白-2（SGLT-2）和相关疾病，病症和病症来调节或归一化的病症或疾病的治疗。

公开(公告)号：WO2010068386A1

公开(公告)日：2010-06-17

申请号：PCT/US2009/065226

申请日：2009-11-20

Applicant: GENERAL ELECTRIC COMPANY ,  GUPTA, Sudhir, Kumar ,  KUMAR, Ajith, Kuttannair ,  WORDEN, Bret, Dwayne ,  DAIGLE, Jeffrey, Louis ,  NIKOLOV, Emil ,  IOANNIDIS, Dimitrios

Inventor： GUPTA, Sudhir, Kumar ,  KUMAR, Ajith, Kuttannair ,  WORDEN, Bret, Dwayne ,  DAIGLE, Jeffrey, Louis ,  NIKOLOV, Emil ,  IOANNIDIS, Dimitrios

IPC: B60L1/00 ,  B60L9/00 ,  H03H1/00

CPC classification number: B60L1/003 ,  B60L9/005 ,  B60L2200/26 ,  B60L2270/147 ,  H03H1/0007 ,  Y10T307/398

Abstract: Power system and method for providing electrical power are provided. The system includes a traction system and auxiliary equipment coupled to a power bus. The traction system includes one or more electromotive machines having a first type of stator winding that provides protection relative to voltage spikes expected at the traction stator under a first voltage level appropriate for the traction system. The auxiliary equipment includes one or more electromotive machines having a second type of stator winding that provides protection relative to spikes expected at the auxiliary stator under a second voltage level lower than the first voltage level. Inverter circuitry is coupled to drive the auxiliary equipment, and signal-conditioning circuitry is provided to attenuate voltage spikes produced by the inverter circuitry. The power bus is operated at the first voltage level, and the voltage spike attenuation is sufficient to protect the auxiliary stator.

Abstract translation: 提供了用于提供电力的电力系统和方法。 该系统包括牵引系统和耦合到电力总线的辅助设备。 该牵引系统包括一个或多个电动机，其具有第一类型的定子绕组，其相对于牵引定子处的预期的电压尖峰在适于牵引系统的第一电压水平下提供保护。 辅助设备包括具有第二类型的定子绕组的一个或多个电动机，其在低于第一电压电平的第二电压电平下相对于在辅助定子处预期的尖峰提供保护。 逆变器电路被耦合以驱动辅助设备，并且提供信号调节电路以衰减由逆变器电路产生的电压尖峰。 电源总线工作在第一电压电平，电压尖峰衰减足以保护辅助定子。

公开(公告)号：WO2007122634A2

公开(公告)日：2007-11-01

申请号：PCT/IN2007/000157

申请日：2007-04-23

Applicant: JUBILANT BIOSYS LIMITED ,  BALAJI, Vituduki, Narayana, Iyengar ,  PRASANNA, Marahanakuli, Dattatreya ,  SAMIRON, Phukan ,  SUDHIR KUMAR, Singh

Inventor： BALAJI, Vituduki, Narayana, Iyengar ,  PRASANNA, Marahanakuli, Dattatreya ,  SAMIRON, Phukan ,  SUDHIR KUMAR, Singh

IPC: C07D405/04 ,  C07D409/04 ,  A61K31/513 ,  A61P25/28

CPC classification number: C07D409/04 ,  C07D405/04

Abstract: The present invention relates to a compound of formula (I) or its stereoisomers, tautomers, solvates, hydrates, prodrugs, pharmaceutically acceptable salts or mixtures thereof, wherein A1 is nitrogen; A2 is carbon; Rl is independently selected from the group consisting of aryl or 5-6 membered heterocyclic ring system; R2 and R3 are independently selected from the group consisting of H, alkyl, substituted alkyl, alkylaryl, alkylheteroaryl, aryl, or 5-6 membered heterocyclic ring system; provided R2 or R3 is H. The present invention also provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier or diluents. The present invention also provides a method for the prophylaxis or treatment of a medical condition associated with protein kinase, by administering a pharmaceutically effective amount of the compound of formula (I) or salts thereof.

Abstract translation: 本发明涉及式（I）化合物或其立体异构体，互变异构体，溶剂合物，水合物，前药，药学上可接受的盐或其混合物，其中A1为氮; A2是碳; R1独立地选自芳基或5-6元杂环系; R2和R3独立地选自H，烷基，取代的烷基，烷基芳基，烷基杂芳基，芳基或5-6元杂环系; 本发明还提供了包含式（I）化合物或其药学上可接受的盐与药学上可接受的载体或稀释剂组合的药物组合物。 本发明还提供了一种通过施用药学有效量的式（I）化合物或其盐来预防或治疗与蛋白激酶相关的医学病症的方法。

公开(公告)号：WO03041653A3

公开(公告)日：2003-07-10

申请号：PCT/US0236604

申请日：2002-11-14

Applicant: UNIV RUTGERS ,  LAVOIE EDMOND J ,  RUCHELMAN ALEXANDER L ,  SINGH SUDHIR KUMAR ,  RAY ABHIJIT ,  LIU LEROY FONG

Inventor： LAVOIE EDMOND J ,  RUCHELMAN ALEXANDER L ,  SINGH SUDHIR KUMAR ,  RAY ABHIJIT ,  LIU LEROY FONG

IPC: A61K31/503 ,  A61P35/00 ,  C07D487/14 ,  C07D491/14 ,  C07D237/26 ,  A61K31/4355 ,  A61K31/4741 ,  A61K31/5025 ,  C07D491/147 ,  C07D491/153 ,  C07D491/22

CPC classification number: C07D491/14 ,  C07D491/147 ,  C07D491/22 ,  C12N5/0693 ,  C12N2501/06 ,  C12N2501/999

Abstract: The invention provides compounds of the invention pharmaceutical compositions comprising a compound of the invention, processes for preparing compounds of the invention, intermediates useful for preparing compounds of the invention, and therapeutic methods for treating cancer and other topoisomerase mediated conditions.

Abstract translation: 本发明提供了本发明化合物，其包含本发明化合物的药物组合物，用于制备本发明化合物的方法，用于制备本发明化合物的中间体，以及用于治疗癌症和其它拓扑异构酶介导的病症的治疗方法。

公开(公告)号：WO2021203290A1

公开(公告)日：2021-10-14

申请号：PCT/CN2020/083737

申请日：2020-04-08

Applicant: QUALCOMM INCORPORATED ,  CHENG, Peng ,  PALADUGU, Karthika ,  CHENG, Hong ,  BAGHEL, Sudhir Kumar ,  GULATI, Kapil ,  HORN, Gavin, Bernard ,  HOSSEINI, Seyedkianoush ,  LI, Junyi ,  VASSILOVSKI, Dan

Inventor： CHENG, Peng ,  PALADUGU, Karthika ,  CHENG, Hong ,  BAGHEL, Sudhir Kumar ,  GULATI, Kapil ,  HORN, Gavin, Bernard ,  HOSSEINI, Seyedkianoush ,  LI, Junyi ,  VASSILOVSKI, Dan

IPC: H04W72/04 ,  H04W76/14 ,  H04W48/16

Abstract: Certain aspects provide a method for wireless communication by a first user-equipment (UE). The method generally includes determining a first configuration for communication with a second UE of one or more discovery messages on a sidelink channel and a second configuration for data communication with the second UE on the sidelink channel, wherein the first configuration is different than the second configuration, and communicating with the second UE in accordance with at least one of the first configuration or the second configuration.

公开(公告)号：WO2021068159A1

公开(公告)日：2021-04-15

申请号：PCT/CN2019/110341

申请日：2019-10-10

Applicant: QUALCOMM INCORPORATED ,  GUO, Hui ,  BAGHEL, Sudhir Kumar ,  NGUYEN, Tien Viet

Inventor： GUO, Hui ,  BAGHEL, Sudhir Kumar ,  NGUYEN, Tien Viet

IPC: H04W72/04

Abstract: Techniques for handling sidelink feedback signaling in situations where collisions would otherwise be experienced in a network communication link are shown and described. For example, sidelink feedback signaling handling techniques may provide for collision handling when sidelink HARQ is to be simultaneously transmitted with network communication radio interface uplink channel information (e.g., Uu HARQ, SR, CSI, etc.) on one or more Uu channel (e.g., PUCCH, PUSCH, etc.). In operation of sidelink feedback handling, a transmitter or intermediary UE of a sidelink communication link may decide whether and how to forward the sidelink HARQ to a corresponding base station. Other aspects and features are also claimed and described.